Ruxolitinib inhibits the JAK/STAT signaling pathway, blocking aberrant proliferation and survival signals induced by CRLF2 rearrangement. This overcomes the TSLPRCART resistance in ALL PDXs. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.